Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(26 sites)
United States
UC San Diego Moores Cancer Center, La Jolla, California Keck Medicine of USC Koreatown, Los Angeles, California Los Angeles General Medical Center, Los Angeles, California USC / Norris Comprehensive Cancer Center, Los Angeles, California Sibley Memorial Hospital, Washington D.C., District of Columbia UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida University of Miami Sylvester Comprehensive Cancer Center at Sole Mia, North Miami, Florida UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia Northwestern University, Chicago, Illinois Memorial Hospital East, Shiloh, Illinois University of Kentucky/Markey Cancer Center, Lexington, Kentucky Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri Washington University School of Medicine, St Louis, Missouri Siteman Cancer Center-South County, St Louis, Missouri Siteman Cancer Center at Christian Hospital, St Louis, Missouri NYU Langone Hospital - Long Island, Mineola, New York Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah